Compare TXRH & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXRH | PODD |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 10.3B |
| IPO Year | 2004 | 2007 |
| Metric | TXRH | PODD |
|---|---|---|
| Price | $168.04 | $149.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 21 |
| Target Price | $193.78 | ★ $341.48 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.87 | 1.30 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $13.46 | $24.55 |
| Revenue Next Year | $9.28 | $19.18 |
| P/E Ratio | ★ $89.64 | $114.70 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $153.83 | $140.63 |
| 52 Week High | $197.00 | $354.88 |
| Indicator | TXRH | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 43.50 |
| Support Level | $165.83 | $143.11 |
| Resistance Level | $177.65 | $205.95 |
| Average True Range (ATR) | 5.70 | 5.92 |
| MACD | -1.56 | 2.29 |
| Stochastic Oscillator | 31.67 | 43.41 |
Texas Roadhouse Inc is a restaurant company operating predominantly in the casual dining segment. The company manages its restaurant and franchising operations by concept and, as a result, has identified Texas Roadhouse, Bubba's 33, Jaggers, and retail initiatives as separate operating segments. In addition, it has identified Texas Roadhouse and Bubba's 33 as reportable segments. Maximum revenue for the company is generated from the Texas Roadhouse segment, which is a moderately priced, full-service, casual dining restaurant concept offering steaks, a selection of ribs, seafood, chicken, pork chops, pulled pork, vegetable plates, and an assortment of hamburgers, salads, and sandwiches. Geographically, the majority of the firm's restaurants are in the USA, with a few in foreign countries.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.